Kiniksa Pharmaceuticals Ltd - Asset Resilience Ratio
Kiniksa Pharmaceuticals Ltd (KNSA) has an Asset Resilience Ratio of 33.70% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2025)
This chart shows how Kiniksa Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Check Kiniksa Pharmaceuticals Ltd strategic asset allocation index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Kiniksa Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Kiniksa Pharmaceuticals Ltd (KNSA) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $278.14 Million | 33.7% |
| Total Liquid Assets | $278.14 Million | 33.70% |
Asset Resilience Insights
- Very High Liquidity: Kiniksa Pharmaceuticals Ltd maintains exceptional liquid asset reserves at 33.70% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Kiniksa Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio
Compare Kiniksa Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Almirall S.A.
MC:ALM |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Fujian Cosunter Pharmaceutical Co Ltd
SHE:300436 |
Drug Manufacturers - Specialty & Generic | -2.56% |
|
ANI Pharmaceuticals Inc
NASDAQ:ANIP |
Drug Manufacturers - Specialty & Generic | 0.63% |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089 |
Drug Manufacturers - Specialty & Generic | 10.89% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
Annual Asset Resilience Ratio for Kiniksa Pharmaceuticals Ltd (2016–2025)
The table below shows the annual Asset Resilience Ratio data for Kiniksa Pharmaceuticals Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 32.54% | $248.48 Million | $763.63 Million | +22.20pp |
| 2024-12-31 | 10.34% | $60.05 Million | $580.55 Million | -8.36pp |
| 2023-12-31 | 18.70% | $98.42 Million | $526.32 Million | +3.93pp |
| 2022-12-31 | 14.77% | $67.89 Million | $459.67 Million | -10.89pp |
| 2021-12-31 | 25.66% | $59.73 Million | $232.80 Million | -34.28pp |
| 2020-12-31 | 59.93% | $209.44 Million | $349.46 Million | -13.32pp |
| 2019-12-31 | 73.25% | $186.45 Million | $254.53 Million | +0.16pp |
| 2018-12-31 | 73.09% | $235.33 Million | $321.96 Million | +72.87pp |
| 2017-12-31 | 0.22% | $105.00K | $47.49 Million | +0.04pp |
| 2016-12-31 | 0.19% | $105.00K | $56.47 Million | -- |
About Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-3… Read more